CSPCY (CSPC Pharmaceutical Group) EBIT : $915 Mil (TTM As of Jun. 2024)

View and export this data going back to 2018. Start your Free Trial

What is CSPC Pharmaceutical Group EBIT?

CSPC Pharmaceutical Group's earnings before interest and taxes (EBIT) for the three months ended in Jun. 2024 was $242 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2024 was $915 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. CSPC Pharmaceutical Group's annualized ROC % for the quarter that ended in Jun. 2024 was 19.70%. CSPC Pharmaceutical Group's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was 57.50%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. CSPC Pharmaceutical Group's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was 15.48%.

CSPC Pharmaceutical Group EBIT Historical Data

The historical data trend for CSPC Pharmaceutical Group's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CSPC Pharmaceutical Group EBIT Chart

CSPC Pharmaceutical Group Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT

Get a 7-Day Free Trial

664.21

979.20

1,076.22

1,091.15

1,038.52

CSPC Pharmaceutical Group Quarterly Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
EBIT	Get a 7-Day Free Trial															265.06	250.50	286.65	242.43	135.06

Competitive Comparison of CSPC Pharmaceutical Group's EBIT

For the Drug Manufacturers - General subindustry, CSPC Pharmaceutical Group's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CSPC Pharmaceutical Group's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, CSPC Pharmaceutical Group's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where CSPC Pharmaceutical Group's EV-to-EBIT falls into.

CSPC Pharmaceutical Group EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $915 Mil.

CSPC Pharmaceutical Group (OTCPK:CSPCY) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

CSPC Pharmaceutical Group's annualized ROC % for the quarter that ended in Jun. 2024 is calculated as:

	ROC % (Q: Jun. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Mar. 2024 )	+	Invested Capital (Q: Jun. 2024 ))	/ count )
=	907.092 * ( 1 - 18.44% )	/	( (0	+	3756.323)	/ 1 )
=	739.8242352	/	3756.323
=	19.70 %

where

	Invested Capital		(Q: Mar. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0	-	0	-	( 0	-	max(0, 0	-	0	+	0	))
=	0

	Invested Capital		(Q: Jun. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	6602.112	-	1358.26	-	( 1487.529	-	max(0, 1438.42	-	3648.152	+	1487.529	))
=	3756.323

Note: The Operating Income data used here is four times the quarterly (Jun. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

CSPC Pharmaceutical Group's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Jun. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Mar. 2024		Q: Jun. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	969.724	/	( ( (0 + max(0, 0))	+	(1686.456 + max(-1.0489999999998, 0)) )	/	1 )
=	969.724	/	( ( 0	+	1686.456 )	/	1 )
=	969.724	/	1686.456
=	57.50 %

where Working Capital is:

	Working Capital		(Q: Mar. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0)	-	(0	+	0	+	0)
=	0

	Working Capital		(Q: Jun. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(874.354	+	450.841	+	67.715)	-	(1358.26	+	0	+	35.699)
=	-1.0489999999998

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Jun. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

CSPC Pharmaceutical Group's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Jun. 2024 )
	=	914.649	/	5908.983
	=	15.48 %

CSPC Pharmaceutical Group EBIT Related Terms

Thank you for viewing the detailed overview of CSPC Pharmaceutical Group's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

CSPC Pharmaceutical Group Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » CSPC Pharmaceutical Group Ltd (OTCPK:CSPCY) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

CHJTF:USA 01093:Hong Kong CVG:Germany

Address

No. 226 Huanghe Street, Hebei Province, Shijiazhuang, CHN, 050035

Website

https://www.cspc.com.hk

CSPC Pharmaceutical Group listed on the Hong Kong Stock Exchange in 1994 and is one of the largest pharmaceutical companies in China. Its biggest business segment is the finished drugs segment which accounts for nearly 80% of its total revenue. Now it has a diversified pipeline portfolio in seven therapeutic areas including nervous system diseases, oncology, anti-infective to cardiovascular disease, respiratory system disease, and metabolism. CSPC also has a bulk drug product segment including vitamin C, antibiotics, and a caffeine series.

CSPC Pharmaceutical Group Headlines

From GuruFocus

Value Partners Classic Fund Comments on CSPC Pharmaceutical

By Vera Yuan Vera Yuan • 07-29-2014